A novel approach for an immunogen against Corynebacterium pseudotuberculosis infection: An Escherichia coli bacterin expressing phospholipase D.
Caseous lymphadenitis
Recombinant bacterin
Vaccines
Virulence factor
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
30
09
2020
revised:
12
01
2021
accepted:
13
01
2021
pubmed:
25
1
2021
medline:
22
6
2021
entrez:
24
1
2021
Statut:
ppublish
Résumé
Corynebacterium pseudotuberculosis is the causative agent of caseous lymphadenitis (CLA) in small ruminants. There is still needed an immunoprophylaxis model, which induces a protective and sustained immune response against the bacteria. In this study, we evaluated a recombinant Escherichia coli bacterin expressing the recombinant phospholipase D (rPLD) protein, the most relevant virulence factor of C. pseudotuberculosis, as a potential vaccine formulation. E. coli BL21 (DE3) Star strain was used for rPLD protein expression and was then inactivated by formaldehyde. Four groups with 10 Balb/c mice each were immunized twice within a 21 days interval: G1-control - 0.9% saline solution; G2- E. coli bacterin/pAE (naked plasmid); G3- E. coli bacterin/pAE/pld; G4-purified recombinant rPLD. Subsequently, the animals were challenged with a C. pseudotuberculosis virulent strain and evaluated for 40 days. The highest survival rate was observed for G3 with 40% protection, followed by 30% in the purified rPLD group (G4). These two groups also showed considerable IgG production when compared with the control group (G1). Also, a higher significant expression of interferon-γ was observed for the experimental groups G2, G3, and G4 when compared with a control group (G1) (p < 0.05). These results represent that a recombinant bacterin can be seen as a promising approach for vaccinal antigens against CLA, being possible to be used in association of different vaccine strategies.
Identifiants
pubmed: 33485993
pii: S0882-4010(21)00018-8
doi: 10.1016/j.micpath.2021.104746
pii:
doi:
Substances chimiques
Bacterial Vaccines
0
Phospholipase D
EC 3.1.4.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104746Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.